OBLN: Obalon Therapeutics is a Sell

The current rating for OBLN is 41, which is 22% below its historic median rating of 50. This indicates higher risk than normal.

The rating is currently showing a lower than normal reading, suggesting risk levels could be higher than normal and additional caution is advised.